scholarly journals Prevention and Treatment of Thromboembolism in Patients with Inflammatory Bowel Disease

2015 ◽  
Vol 65 (3) ◽  
pp. 151
Author(s):  
Jae Jun Park
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Prevention And Treatment ◽  
Inflammatory Bowel

The Effect of Dietary Glutathione and Coenzyme Q10 on the Prevention and Treatment of Inflammatory Bowel Disease in Mice

2004 ◽  
Vol 74 (1) ◽  
pp. 74-85 ◽  
Author(s):  
Liu ◽  
Russell ◽  
Smith ◽  
Bronson ◽  
Milbury ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Dextran Sulfate ◽  
Coenzyme Q ◽  
Histological Evaluation ◽  
Therapeutic Effects ◽  
Prevention Study ◽  
Prevention And Treatment ◽  
Inflammatory Bowel ◽  
Pre Treatment

Because reactive oxygen species have been implicated as mediators of inflammatory bowel disease (IBD), we evaluated the potential preventive and therapeutic effects of two dietary antioxidants, glutathione (GSH) and coenzyme Q10 (CoQ10) on dextran sulfate sodium (DSS)-induced colitis in mice. Fifty female 8-wk old Swiss-Webster mice were randomly assigned to 4 groups for a pre-treatment 'prevention' study: (1) GSH (1% of diet); (2) CoQ10 (200 mg/kg/d); (3) DSS only (3% of drinking water); (4) control (no treatment). The mice in groups 1 and 2 were fed with GSH or CoQ10 for 21 wks, and the mice in groups 1, 2 and 3 were provided DSS from wk 7 for 4 cycles (1 cycle = 1 wk DSS followed by 2-wk water). Another 50 mice were randomly assigned to 4 groups for a 21-wk 'treatment' study where the mice in groups 1, 2, and 3 were administered DSS for 6 cycles (18 wks) to induce colitis. GSH and CoQ10 were added from wk 7 until the completion of the protocol. Loose stools and hemocult positivity were modestly but significantly reduced with GSH or CoQ10 at several periods during the intervention in both the prevention and treatment studies. In contrast, histological evaluation revealed increases in colonic dysplasia and ulceration with GSH or CoQ10. Thus, in this mouse model, GSH and CoQ10 appear to have a beneficial effect on acute signs of IBD, but may have an adverse impact on the chronic pathophysiology of the disease. Further studies using additional animal models are required to determine whether GSH or CoQ10 provide a favorable or unfavorable benefit:risk ratio in the prevention or treatment of IBD.

scholarly journals Thrombotic Complications in Inflammatory Bowel Disease

2019 ◽  
Vol 29 (2) ◽  
pp. 23-26
Author(s):  
A. V. Borota ◽  
A. A. Borota ◽  
E. V. Onishchenko
Keyword(s):  
Inflammatory Bowel Disease ◽  
Chronic Inflammation ◽  
Bowel Disease ◽  
Intestinal Wall ◽  
Coagulation Cascade ◽  
Coagulation System ◽  
Primary Disease ◽  
Prevention And Treatment ◽  
Thrombotic Complications ◽  
Inflammatory Bowel

The risk of thrombotic complications is known to be 3 times higher in patients with inflammatory bowel disease (IBD) than in healthy individuals, with the relative risk being 15 times higher during the periods of relapses. Aim. To study and generalize literature data available on the prevention and treatment of IBD thrombotic complications.Key findings. In the сonditions under study, the presence of chronic inflammation and increased bleeding of the intestinal wall is shown to activate the coagulation system, impair the fibrinolysis system and reduce the activity of natural anticoagulation mechanisms. The concentration of fibrinogen — a protein of the acute inflammation phase — increases significantly. This results in an imbalance of the blood coagulation system with a tendency to hypercoagulation, which significantly increases the risk of thrombotic complications and the disseminated intravascular coagulation syndrome. In turn, the activation of the coagulation cascade may trigger the inflammatory response, which eventually leads to the formation of a vicious circle between chronic inflammation and thrombosis. The pathogenesis of thrombosis in inflammatory colon diseases is a multifactor process, which remains to be understood.Conclusion.The management of patients with IBD in combination with thromboembolic complications requires an individual multidisciplinary approach. Taking into account the pathogenetic factors, the following options are possible in the prevention and treatment of thrombotic complications in IBD: strengthening the basic therapy of the primary disease; administration of prophylactic doses of anticoagulants under dynamic continuous laboratory control in the acute period using the methods of conservative therapy of thrombotic complications (elastic compression of the lower extremities) in the period of exacerbation of the primary disease.

Examination, Prevention and Treatment of Osteoporosis in Patients with Inflammatory Bowel Disease: Recommendations and Reality

2002 ◽  
Vol 29 (4) ◽  
pp. 120-123 ◽  
Author(s):  
A. Kirchgatterer ◽  
H. H. Wenzl ◽  
G. Aschl ◽  
M. Hinterreiter ◽  
B. Stadler ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Treatment Of Osteoporosis ◽  
Prevention And Treatment ◽  
Inflammatory Bowel

scholarly journals Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease

2016 ◽  
Vol 23 (6) ◽  
pp. 501-510 ◽  
Author(s):  
Huseyin Alkim ◽  
Ali Riza Koksal ◽  
Salih Boga ◽  
Ilker Sen ◽  
Canan Alkim
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Prevention And Treatment ◽  
Inflammatory Bowel

scholarly journals Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Linshan Duan ◽  
Shuyu Cheng ◽  
Long Li ◽  
Yanling Liu ◽  
Dan Wang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Disease Recurrence ◽  
Natural Compounds ◽  
Ginsenoside Rd ◽  
Novel Approach ◽  
Prevention And Treatment ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Inflammatory bowel disease (IBD) represents chronic recurrent intestinal inflammation resulting from various factors. Crohn’s disease (CD) and ulcerative colitis (UC) have been identified as the two major types of IBD. Currently, most of the drugs for IBD used commonly in the clinic have adverse reactions, and only a few drugs present long-lasting treatment effects. Moreover, issues of drug resistance and disease recurrence are frequent and difficult to resolve. Together, these issues cause difficulties in treating patients with IBD. Therefore, the development of novel therapeutic agents for the prevention and treatment of IBD is of significance. In this context, research on natural compounds exhibiting anti-inflammatory activity could be a novel approach to developing effective therapeutic strategies for IBD. Phytochemicals such as astragalus polysaccharide (APS), quercetin, limonin, ginsenoside Rd, luteolin, kaempferol, and icariin are reported to be effective in IBD treatment. In brief, natural compounds with anti-inflammatory activities are considered important candidate drugs for IBD treatment. The present review discusses the potential of certain natural compounds and their synthetic derivatives in the prevention and treatment of IBD.

Sign in / Sign up

Export Citation Format

Share Document